FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Hogenhuis Wladimir (Last) (First) (Middle) C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT						Issuer Name and Ticker or Trading Symbol Ultragenyx Pharmaceutical Inc. [RARE] 3. Date of Earliest Transaction (Month/Day/Year) 03/01/2019									elationship of Reporting Person(s) to Issuer ick all applicable) Director Officer (give title below) Chief Operating Officer			ner	
(Street) NOVATO CA 94949 (City) (State) (Zip)					4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(5.5)			le I - Nor	n-Deriv	vativ	e Se	curities	s Aca	uired. [Dist	osed o	f. or B	ene	ficiall	v Owned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					saction	ear)	2A. Deemed Execution Date, if any (Month/Day/Year)		3. 4. Transaction Dis		4. Securi	curities Acquired (A) osed Of (D) (Instr. 3, 4			5. Amou Securitie Beneficia	int of 6. Constant of		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amount	(A) or (D)		Price	Transact	ransaction(s) nstr. 3 and 4)			,
Common Stock 03/01/						2019			A		5,000 ⁽¹⁾ A		A	\$0.00	20,0	20,000(2)		D	
		-	Гable II -								sed of, onvertil				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)		Date Exercisable		xpiration ate	Title	OI N Of	umber					
Stock Option (Right to	\$67.55	03/01/2019			A		11,000		(3)	0	3/01/2029	Commo Stock	n 1	1,000	\$0.00	11,000)	D	

Explanation of Responses:

- 1. Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date.
- 2. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- 3. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.

Remarks:

/s/ Ruben A. Garcia, attorney-

<u>in-fact</u>

** Signature of Reporting Person

Date

03/04/2019

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.